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Introduction.
This article contains information from a talk 
given by the author at the RMS on 14/01/03, en­
titled: Statins and Immuno-modulation: A New 
Frontier. Statins repre­
sent one of the major 
successes of cardiology 
in the secondary preven­
tion of coronary artery 
disease. This article at­
tempts to understand the 
very molecule which 
makes many quake in 
their boots, cholesterol, and how basic science 
research continues to find novel methods in 
which statin therapy can participate.
Large scale epidemiological studies in the gen­
eral population, especially  through the 
Framingham Heart study, the largest and most 
comprehensive medical study in the history of 
cardiology and some would say in modem day 
epidemiology, has identified several risk factors 
pertinent to the development of cardiovascular 
disease. The study based in the small town of 
Framingham on the outskirts of Boston, Massa­
chusetts in the USA, has provided the means for 
risk assessment and public health targets in the 
prevention of coronary artery disease. Some of 
these risk factors for coronary artery disease in­
clude age, hypertension, hypercholesterolaemia, 
diabetes, and cigarette smoking '. However, one 
factor that has proved to be, and continues to be, 
one of the great successes of 21st century medi­
cine has been the introduction of the HMG-CoA 
reductase inhibitors. Yet, to better comprehend 
this “magic drug” one has to appreciate the drug’s 
target, that of cholesterol.
Cholesterol.
Cholesterol is a ubiquitous alicyclic compound, 
a member of the lipid family, which is distributed 
in both free and esterified forms throughout the 
body. Cholesterol can exist in a number of 
different structural isomers, from having a single 
hydroxyl group at C-3 to having an unsaturated
centre between the C5 and C-6 atoms (see figure 
1). Physically, cholesterol like other lipids is 
hydrophobic except for a single hydrophilic OH 
group, attached to which 
are several hydrophobic 
rings.
Given the hydrophobic 
nature of cholesterol, it 
is therefore surprising 
that the concentration of 
cholesterol in the plasma 
of healthy people is usually 150-200mg d L 1. The 
high level of solubility of cholesterol in blood is 
attributed to the formation of protein-lipid com­
plexes, called lipoproteins (ie. LDL and VLDL) 
which through the aid of apo-lipoproteins are able 
to bind and hence dissolve large amounts of cho­
lesterol within blood. Physiologically, approxi­
mately 30% of the total circulating cholesterol 
in the human body occurs as free cholesterol, 
whilst the remainder exists as cholesterol esters 
attached to plasma lipoproteins.
Cholesterol is a vital biological molecule, play­
ing an essential role in the architecture of the 
cell membrane, by providing rigidity but also flu­
idity for the flipping of lipids on the cell mem­
brane. Cholesterol is also the precursor for the 
steroid hormones such as the sex hormones Oes­
trogen and Testosterone, and the cortico- and 
mineralocorticosteroids such as cortisol and al­
dosterone respectively. Cholesterol is also
Figure 1. The chemical structure o f Cholesterol.
“Currently the most potent 
treatment for hyperlipidaemia 
are the HMG-CoA reductase 
inhibitors or statins.”
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abundant in bile salts, allowing the process of 
emulsification for fat metabolism.
C h olestero l S yn th esis  -  The M evalonate  
Pathway.
The derivation of cholesterol can either be 
through diet or through de novo biosynthesis, 
which accounts for 45% of the cholesterol in the 
body. Whilst biosynthesis in the liver and the 
small intestines accounts for 10% and 15% 
respectively; other major synthetic sites include 
the adrenal cortex and reproductive tissues. The 
synthesis of cholesterol occurs in the cytoplasm 
and results from the reduction of the high energy 
bonds of ATP and Acetyl-CoA (ACT-CoA). As 
the pre-cursor in the cholesterol pathway ACT- 
CoA is converted to mevalonate via the formation 
of 3-hydroxy-3-methylglutaryl-CoA (HMG- 
CoA). This critical early step is rate-limiting in 
cholesterol synthesis and is regulated by the 
enzyme HMG-CoA reductase.
Upon successive phosphorylations of 
mevalonate and its intermediates an activated 
isoprenoid molecule, Isopentenyl Pyrophosphate, 
(IPP) is produced. Through the subsequent 
condensations of IPP to famesyl pyrophosphate 
(FPP), and through the catalysis of the NADPH- 
requiring enzyme, squalene synthase, squalene 
is produced. It is the cyclisation of squalene to 
Lanosterol that produces the end product of 
cholesterol.
Cholesterol regulation.
The level of cholesterol synthesis can in part be 
regulated through the dietary intake of cholesterol 
and so the cellular level of cholesterol is 
maintained through the following independent 
but interacting mechanisms:
1) Cholesterol levels act as a negative feedback 
inhibitor for HMG-CoA reductase. Additionally, 
during times of excess, there is decreased 
expression of the HMG-CoA reductase gene 
resulting in low levels of mRNA for translation 
of HMG-CoA reductase.
2) The activity of HMG-CoA reductase is varied
through covalent modification. This is achieved
through either phosphorylating or
dephosphorylating the enzyme, whereby
phosphorylation of the enzyme reduces its 
activity. Phosphorylation is stimulated in context 
to the levels of cAMP in the body, under the 
hormonal control of insulin and glucagon. 
Increases in cAMP lead to the activation of the 
cAMP-dependent protein kinase, PKA, which in 
turn results in the phosphorylation and an 
increase in the activity of the phosphoprotein 
phosphatase inhibitor-1 (PPI-1). PPI-1 inhibits 
the activity of numerous phosphatases of which 
HMG-CoA reductase is one. It is through this 
method that hormones such as insulin, which 
causes a decrease in cAMP levels, leads to the 
activation of cholesterol synthesis.
3) Finally, both LDL and HDL receptor-mediated 
transport can also regulate plasma cholesterol 
levels. This process is based on the active uptake 
of excess hepatic cholesterol from the liver into 
the serum through LDL . Cholesterol in plasma 
membranes can be later extracted and esterified 
by HDL in the peripheral tissues. Cholesterol is 
finally excreted in the bile either in the form of 
bile salts or as free cholesterol.
HMG-CoA reductase inhibitors -  Statins.
Currently the most potent treatm ent for 
hyperlipidemia are the HMG-CoA reductase 
inhibitors or statins. In 2000, statins were the sec­
ond most popular drug in terms of sales , with 
sales of $15.9 billion - up 21% from 1999.2 
Statins are HMG-CoA reducatase inhibitors, 
inhibiting the rate limiting enzyme HMG-CoA 
reducatase which conducts the breakdown of 
HMG-CoA to mevalonate, vital for the synthe­
sis of cholesterol and isoprenoids further down­
stream in the pathway.
Statins are used extensively in current medical 
practice as a proven method of lowering blood 
lipid levels. Through numerous clinical trials this 
class of drugs have demonstrated their benefit in 
greatly reducing cardiovascular morbidity and 
mortality, as well as in the primary and second­
ary prevention of coronary disease in patients 
with and without coronary artery disease 3-9.
In addition to these clinical trials further in vitro 
and in vivo findings suggest that statins, through 
their highly effective lipid lowering abilities have 
other pleiotropic effects, in particular anti-inflam- 
matory properties.3
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Statins: Anti-inflammatorv Properties.
An association between statin treatment and an 
anti-inflammatory response can be defined from 
markers of acute inflam m ation, including 
cytokines, C reactive protein (CRP) and white 
cell count. Needless to say, all the above factors 
are also indicative of being in a higher coronary 
risk factor group10.
Further analysis into the schematic scenario of 
the atherosclerotic process allowed a definite 
conclusion that the evolution of atherosclerotic 
lesions involves an interaction between four 
major cell types: endothelial cells (ECs), smooth 
muscle cells (SM Cs), m acrophages, and 
lymphocytes. It has since been suggested that 
statins may interfere directly with several key 
mechanisms necessary for the involvement of 
different cellular elements in all the steps of 
atherogenesis.
production within vascular endothelial cells12.
Atherosclerosis over vascular endothelium 
having activated the endothelium has also been 
shown to increase the expression of adhesion 
molecules such as ICAM-1, VCAM-1 and E- 
selectin , vital for the extravasation of 
leuokocytes. Using a rat model Katoh et al. 13 
showed how a particular statin (Fluvastatin) can 
reduce the expression of soluble ICAM-1. This 
result was also seen in hypercholesterolaemic 
patients, where there was also a reduction in the 
level of soluble P-selectin14. In addition statins 
have also been shown to inhibit the monocyte- 
endothelial interaction stimulated by oxidised 
LDL15. It is thought that oxidised LDL is able to 
be chemotactic for monocytes and human T 
lymphocytes16, through inducing the expression 
of factors such as MCP-1 by both human 
endothelial cells and smooth muscle cells 17.
The effect of Statins on endothelial function. 
Since the observation that endothelial 
dysfunction arises early in the presence of 
elevated cholesterol levels11 several experimental 
studies began to explore the effects of statins on 
preserving endothelial function. As a result it has 
shown that statins can alter the bioavailability of 
nitric oxide (NO) through the posttranslational 
up regulation of endothelial NO synthase (eNOS) 
mRNA and the decrease of superoxide anion 
production within vascular endothelial cells.1
The effect of Statins on T-cell function.
It has been demonstrated that statins inhibited 
the Interferon-g (IFN-g)-mediated induction of 
class II major histocompatibility complexes 
(MHC II) on antigen presenting cells, including 
human m onocytes/m acrophages 18. More 
recently, evidence by Weitz-Schmidt has also 
indicated that the statins Lovastatin and 
mevastatin selectively block the lymphocyte 
function associated antigen-1 (LFA-1). LFA-1 is 
involved in the adhesion of leukocytes to the
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Figure 2. The Cholesterol synthesis pathway.
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b ind ing  m o lecu les  ICAM -1 and a lso  in the 
p r o c e s s  o f  ly m p h o c y te  r e - c i r c u l a t i o n  and  
effective T cell activation by antigen presenting 
cells. Statin-induced LFA-1 inhibition resulted 
in a d e c r e a s e  in ly m p h o c y te  a d h e s io n  to 
ICAM-1 and impaired T-cell co-stimulation 19.
As research continues into these and the other 
pleiotropic effects of  statins, we can expect a new 
generation o f  cholesterol reduction drugs which 
are able to target a num ber  o f  the secondary 
downstream products in the mevalonate pathway, 
which play an integral part in the inflammatory 
process.
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